Announcement of Shandong Buchang Pharmaceutical Co., Ltd. on changes to the drug production licenses of the company and its wholly-owned subsidiaries
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2026-053
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement on changes to the pharmaceutical production licenses of the company and its wholly-owned subsidiaries
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Buchang Pharmaceutical") has recently obtained permission from the Shandong Provincial Food and Drug Administration, agreeing to changes in the company's production address and production scope, production workshops and production lines, and other contents remain unchanged; Yangling Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as "Yangling Buchang"), a wholly-owned subsidiary of the company, has obtained permission from the Shaanxi Provincial Food and Drug Administration and agreed to changes in the classification code and drug entrustment status of Yangling Buchang's "Drug Production License", and other contents remain unchanged.
The relevant information is now announced as follows:
1. Buchang Pharmaceutical
(1) Information related to drug production license
Company name: Shandong Buchang Pharmaceutical Co., Ltd.
Residence (business place): No. 369, Zhonghua West Road, Mudan District, Heze City, Shandong Province
Legal representative: Zhao Tao
License number: Lu20160260
Category code: AhzBzCh
Person in charge of the company: Zhao Chao
Quality manager: Cui Qiaohong
Production person in charge: Xu Xiang
Quality authorized person: Cui Qiaohong
Production address and production scope: No. 1566, Zhonghua West Road, Heze City: tablets, hard capsules, granules, oral solutions; No. 1818, Zhonghua West Road, Heze City: granules, hard capsules, pills; No. 369, Zhonghua West Road, Mudan District, Heze City, Shandong Province: tablets, hard capsules, granules, pills (honey pills, concentrated pills, water pills, water honey pills), oral liquid***
Valid until May 25, 2030
(2) Changes in copies of drug production licenses
Agree with the company to reduce the production address and production scope: No. 1668, Zhonghua West Road, Heze City (shared with the traditional Chinese medicine pre-treatment and extraction workshop of Shandong Buchang Shenzhou Pharmaceutical Co., Ltd. within the group), production workshop and production line: extraction second workshop (including spray drying facilities in the first area), traditional Chinese medicine pre-treatment and extraction production line, production scope: Xuanfei Baidu Granules dry extract powder.
2. Yang Ling’s step length
(1) Information related to drug production license
Company name: Yangling Buchang Pharmaceutical Co., Ltd.
Registered address: Xinqiao South Road, Yangling Demonstration Zone, Shaanxi Province
Legal representative: Wang Yimin
License number: Shaanxi 20200003
Category code: AhzBhzChz
Person in charge of the company: Zhang Wei
Quality manager: Feng Yu
Production person in charge: Xu Nan
Quality authorized person: Li Fengbo
Production address and production scope: Xinqiao South Road, Yangling Demonstration Zone, Shaanxi Province: Tablets (including anti-tumor products and hormone products), hard capsules (including anti-tumor products), granules, mixtures, syrups (including Chinese medicine pre-treatment and Chinese medicine extraction), oral solutions (entrusted production)***
Valid until: February 6, 2030
(2) Changes in copies of drug production licenses
Shaanxi Buchang Pharmaceutical Co., Ltd. is entrusted to produce Kechuanan Oral Liquid (National Drug Approval Number Z20026982) (only for holder change), production address: No. 123, West Extension Section of Weiyang West Road, Xianyang City.
3. Impact on listed companies and risk warnings
The "Pharmaceutical Production License" involves changes in the production address and production scope, production workshops and production lines, classification codes and drug consignment status, which is conducive to the company's optimization of production structure, conducive to continuing to maintain stable production capacity, meeting market demand, and having a positive impact on the company's future operations.
Since pharmaceutical products are high-tech, high-risk, and high-value-added, the early stage of drug research and development and the product development, clinical trial approval, and production have long cycles and many links, and are easily affected by some uncertain factors. Investors are advised to make prudent decisions and pay attention to guarding against investment risks.
Announcement is hereby made.
Board of Directors of Shandong Buchang Pharmaceutical Co., Ltd.
April 29, 2026